

Date: 10.02.2020

To, The Secretary, The B.S.E Limited Floor 25, P.J. Towers, Dalal Street, Mumbai - 400 001

Sub: Submission of Un-Audited Standalone Financials Results of the Company and Limited Review Report as per Provisions of Regulation 30, 33 of SEBI (LODR) Regulations, 2015.

Please find enclosed here with the following Documents in terms of Regulation 33 of the SEBI (LODR) Regulations, 2015:

- 1. Financial Results: Un-Audited Standalone & Consolidated Financial Results of the company for the Third Quarter Ended 31st December, 2019.
- Limited Review Report: A Certified Copy of the Limited Review Report on Standalone Financials for the Third Quarter Ended 31st December, 2019 by the Auditors.

This is for your Information and Necessary Records.

Thanking you

For TRIMURTHI LIMITED

Arun Kumar Bhangadia

Managing Director

DIN: 00021024

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.) 4-4-231/1/2/ABC, Inderbagh, Sultanbazar, Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370



Date: 10/02/2020

To, The Secretary, The B.S.E Limited Floor 25, P.J. Towers, Dalal Street, Mumbai- 400 001

Sub: Outcome of the Board Meeting held on 10/02/2020 as per Regulation 30, 33 of SEBI (LODR) Regulations, 2015

Dear Sir/Madam,

The Board of Directors of the Company at its meeting held today, Monday, the 10th Day of February, 2020 at Registered Office, have approved and taken on record the following:

- 1. The Board has considered and approved the minutes of the previous board meeting.
- 2. The Board has considered and approved the Unaudited Standalone & Consolidated Financial Results for the Third Quarter ended 31st December, 2019 along with Limited Review Report issued by the Statutory Auditors of the Company in compliance with Indian Accounting Standards (Ind-AS), SEBI (LODR) Regulations, 2015 and Schedule III of Companies Act, 2013.

There being no other matter meeting of the Board of Directors concluded with the vote of thanks.

The Meeting of the Board of Directors of the company commenced at 03.30 P.M. and Concluded at 04:30 P.M.

Request you to take same on records.

Thanking you

For TRIMURTHI LIMITED

Arun Kuma Bhangadia

Managing Director DIN: 00021024

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.) 4-4-231/1/2/ABC, Inderbagh, Sultanbazar,

Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370

#### TRIMURTHI LIMITED

# 4-4-231/1/2/ABC, Inder Bagh, Sultan Bazar, Hyderabad - 500095. STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 2019



Rs. in lakhs except share data

NINE MONTHS ENDED MEAR ENDED QUARTER ENDED 31,12,2018 31.12.2019 R(31/03/2019 31.12.2018 30.09.2019 (UNAUDITE (UNAUDITE 31.12.2019 (AUDITED) PARTICULARS (UNAUDITED) (UNAUDITED) (UNAUDITED) 359.19 310.36 52.20 98 89 1. INCOME 14.73 2.10 36.90 INCOME FROM OPERATIONS (0.31 8.26 11.90 312.45 372.43 OTHER INCOME 89.10 98.57 23.00 30.24 TOTAL INCOME 277.05 250.31 2. EXPENSES 89.56 48.41 18.37 12 94 **PURCHASES** COST OF MATERIALS CONSUMED 0.03 (0.14)MANUFACTURING EXPENSES 3 57 (7.30)1 52 2.25 3.00 WORK IN PROGRESS AND STOCK IN TRADE 0.90 1.00 0.30 0.60 32.72 24.65 21.40 9 95 7.35 8.57 EMPLOYEE BENEFITS EXPENSE 12.15 6.90 8.81 1.97 2.80 FINANCE COSTS 2.26 28.39 21.69 DEPRECIATION AND AMORTISATION EXPENSES 16.91 2.17 4.55 355.34 OTHER EXPENSES 98.10 307.58 98.18 34.36 31.67 TOTAL EXPENSES 3. PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE 19.08 (9.00)4.88 0.39 (11.36) (1.42 EXCEPTIONAL ITEMS (1-2) 4. EXCEPTIONAL ITEMS/ PRIOR PERIOD ITEMS 19.08 4 88 (9.00) 0.39 (11.36)PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE TAX (3 (1.42) (54.92)(9.44)0.06 (4.74)(1.02)0.01 6. TAX EXPENSES 0.70 4.49 0.70 (1.10)-CURRENT TAX -TAX ADJUSTMENTS RELATING TO EARLIER YEARS (10.04)(10.14)0.06 0.08 (5.44 0.01 -DEFERRED TAX (NET) 7. NET PROFIT/(LOSS) FROM ORDINARY ACTIVITIES AFTER 25.00 (9.06)14.31 5.13 (10.34)(1.43)8.PROFIT /(LOSS) FROM DISCONTINUED OPERATIONS 9.TAX EXPENSES FOR DISCONTINUED OPERATIONS 10.PROFIT /(LOSS) FROM DISCONTINUED OPERATIONS (AFTER TAX) (8-9) 25.00 14.31 (9.06) 5.13 (10.34)(1.43)11.PROFIT/(LOSS) FOR THE PERIOD (7+10) 12.OTHER COMPREHENSIVE INCOME LOSS (ii) INCOME TAX RELATING TO ITEM THAT THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS (10.12)(6.20)(1.42) (2.30)0.67 B. (i) ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS (0.19)(ii) INCOME TAX RELATING TO ITEM THAT THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS 13.TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (11+12) (COMPRISING PROFIT (LOSS) AND OTHER 18.80 (10.49)4.19 2.82 (9.67)(1.62)COMPREHENSIVE INCOME) 14.EARNINGS PER EQUITY SHARE (FOR CONTINUING 0.31 OPERATION): (0.11)0.18 0.06 (0.02) (0.13)0.31 (i) BASIC (0.11)0.18 0.06 (0.13) (0.02)(ii) DILUTED 15.EARNINGS PER EQUITY SHARE (FOR DISCONTINUING OPERATION): (i) BASIC 16.EARNINGS PER EQUITY SHARE (FOR CONTINUING AND DISCONTINUING OPERATION): 0.31 0.18 0.06 (0.09) (0.13)(0.02)(0.09) (i) BASIC (0.02 (ii) DILUTED



### TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.) 4-4-231/1/2/ABC, Inderbagh, Sultanbazar, Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370

### TRIMURTHI LIMITED SCHEDULE III OF THE COMPANIES ACT 2013 PART-II



		OUARTER ENDEL	)	NINE MONT	HS ENDED	YEAR ENDED
PARTICULARS	31.12.2019 (UNAUDITED)	30.09.2019 (UNAUDITED)	31.12.2018 (UNAUDITED)	31.12.2019 (UNAUDITE D)	31,12,2018 UNACDITE D)	(AUDITAD)
A. PARTICULARS OF SHARE HOLDING						20.00 (00
A. PARTICULARS OF SHARE HOLDING		29,00,600	29,00,600	29,00,600	29,00,600	29,00,600
. Public Share Holding	29,00,600	35.18%	35.81%		35.81%	35.81%
- Number of Shares	35.81%	33.10 /0	3010411			
- Percentage of shareholding Promoters and promoter group shareholding						
a. Pledged / encumbured		-	-	-	-	
	-	-		-	-	-
	-	-		-	-	
Percentage of Shares (of the shareholding of promoter and     Percentage of Shares (of the total share capital of the company)				-1 00 100	51,99,400	51,99,400
b. Non encumbured	51,99,400	51,99,400	51,99,400			100 000/
A CE II. Change	100.00%		100.009			
Use and ago of Shares (of the shareholding of promoter and	64.19%		64.199	64.19%	04.1970	011111
- Percentage of Shares (of the total share capital of the company)	01.17/					

	3 Months Ended ( 31/12/2019)
Particulars	
Investor Complaints	
Pending at the beginning of the quarter	
Received during the quarter	
Disposed during the quarter Remaining unsolved during the quarter	

#### TRIMURTHI LIMITED Segment Reporting

		egment reporting			NINE MONT	US ENDED	YEAR ENDED
			QUARTER ENDEL	NINE MONT			
	PARTICULARS	31.12.2019 (UNAUDITED)	30.09.2019 (UNAUDITED)	31.12.2018 (UNAUDITED)	31.12.2019 (UNAUDITE D)	31.12.2018 (UNAUDITE D)	31.03.2019 (AUDITED)
	Segment Revenue						-
	a. Pharma Business		0.21	14.13	31.89	44.94	57.64
	b. Financial Services	10.80	8.21 0.06	(0.23)	5.01	1.85	12.99
	c. Investments	1.10		3.56	52.20	20.83	30.81
	d. Trading in Shares	18.34	14.73	81.10	-	244.82	270.99
	e. Foods	-	-	98.56	89.10	312.45	372.43
otal		30.24	23.00	98.30	07.10	-	
oce	Inter Segment Revenue		-	98.56	89.10	312.45	372.43
L-4.6	Sales/ Income From Operations	30.24	23.00	98.30	07.10	0.1	
	Segment Profits ( Before tax & Interest From Each Segment)		-		-		-
	a. Pharma Business		15.05	11.85	31.89	36.68	45.45
	b. Financial Services	10.80	0.06	(0.23		1.85	12.99
_	c. Investments				-	9.16	13.97
	d. Trading in Shares	(13.32	(20.11)	(13.67	-	(42.82)	
	e. Foods	(1.42	(11.00)			4.88	19.08
Tota	1	(1.42	(11.00)				
Less			-		-	-	-
_	i. Interest	-		-	-	-	-
	ii. Other Un-allocable expenses net off	-		-	-	-	
_	iii. Un-allocable Income	(1.42	(11.00	0.40	(9.00	4.88	19.08
	Total Profit Before Tax	(1.42	(12100	"			
3.	Capital Employed	29.50		-	29.50	-	-
	a. Pharma Business	369.90		537.9	6 369.90		
	b. Financial Services	30.19			4 30.19		
	c. Investments	460.9			0 460.97		
	d. Trading in Shares	300.0			5 300.00	12.15	
	e. Foods	1,190.5	_		3 1,190.5	6 1,186.43	1,201.0

#### Notes:

Previous period figures have been regrouped, wherever necessary, for the purpose of comparison.


The financial results were reviewed by the Audit Committee and then approved at the meeting of the Board of Directors of the Company held on

The above standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34-Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued there under and the other accounting principles generally accepted in India.

Place: Hyderabad Date: 10-02-2020

### TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.) 4-4-231/1/2/ABC, Inderbagh, Sultanbazar, Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370



Tel. : (91-40) 2332 6666, 2331 2554 2339 3967, 2332 1470

Fax : (91-40) 2339 2474 E-mail : pmurali.co@gmail.com


info@pmurali,com Website: www.pmurali.com


## Limited Review Report- Standalone Financial Results

To
The Board of Directors,
Trimurthi Limited,
Hyderabad.

Limited Review Report on unaudited standalone financial results for the Quarter and Nine Month ended  $31^{th}$  December 2019

- 1. We have reviewed the accompanying statement of unaudited standalone financial results of Trimurthi Limited ("the Company") for the quarter ended 31th December 2019 and year to date results for the period 1stApril 2019 to 31th December 2019 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including relevant circulars issued by SEBI from time to time.
- 2. The preparation of "the Statement" in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India read with circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company in their meeting held on 10th February 2020. Our responsibility is to issue a report on the Statement based on our review.
- 3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.





: (91-40) 2332 6666, 2331 2554 2339 3967, 2332 1470

: (91-40) 2339 2474 Fax E-mail: pmurali.co@gmail.com

info@pmurali.com

Website: www.pmurali.com

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation, read with Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co. **Chartered Accountants** 

FRN: 007257S

M V TOSHI Partner

M.No. 024784 UDIN: 20024784AAAABX5709

Place: Hyderabad Date: 10-02-2020

# TRIMURTHI LIMITED

#### SCHEDULE III OF THE COMPANIES ACT 2013 CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE NINE MONTHS ENDED 31ST DECEMBER, 2019 PART-I



			QUARTER ENDE	ED	NINE MONTHS ENDED TYPEAR ENDE			
	Particulars	31.12.2019 (UNAUDITED)	30.09.2019 (UNAUDITED)	31.12.2018 (UNAUDITED)	31.12.2019 (UNAUDITED)	31.12.2018 (UNAUDITED)	31.03.2018 (AUDITED)	
I. In	come From Operations							
Ne	et Sales / Income from Operations	252.26	262.26	249.67	758.20	790.53	1,045.9	
Ot	ther Income	14.38	20.18	0.01	38.81	2.80	37.7	
II. To	otal Income	266.64	282.44	249.67	797.01	793.33	1,083.6	
	penses						2,000.0	
a. (	Consumption of Raw Material	154.05	35.59	39.70	221.11	125.39	154.2	
	Purchase of Traded Goods/Shares	119.11	154.42	153.91	411.44	447.57	594.2	
in	(Increase)/Decrease in stock in trade and work Progress	3.30	(0.18)	(18.44)	(6.55)	(17.28)	1.9	
	Manufacturing Expenses	(45.92)	64.39	39.01	57.70	117.00	153.8	
	Employee benefits expense Rent	24.97	26.24	29.82	73.45	75.67	98.6	
	Finance Cost	1.50	1.50	2.20	4.50	5.85	7.8	
	Depreciation	3.01	2.67	2.93	9.38	9.61	12.9	
	Other Expenditure	5.07 11.50	4.73	5.14	15.13	15.49	21.2	
	tal	276.60	10.78	10.02	36.86	40.75	51.1	
Pro	ofit/ (Loss) before Exceptional and Tax (II-	2/0.00	300.13	264.28	823.02	820.05	1,096.0	
III	)	(9.95)	(17.69)	(14.61)	(26.02)	(26.72)	(12.4	
	ceptional Items/Prior Period Items		-		-			
	ofit/ (Loss) before tax (IV-V) x expense:	(9.95)	(17.69)	(14.61)	(26.02)	(26.72)	(12.4	
	Current tax	0.86	(0.50)	(2.81)	3.01	(3.04)	2.3	
	Deferred tax	0.65	(0.94)	1.29	1.86	5.42	10.5	
		0.21	0.44	(4.09)	1.15	(8.46)	(8.1	
con	t Profit/ (Loss) for the period from ntinuing operations (VI-VII)	(10.81)	(17.19)	(11.80)	(29.03)	(23.68)	(14.7	
X. Pro	ofit/(loss) from discontinued operations	-	-	-	-			
X. Tax	x expenses of discontinued operations	-	-	-	-			
(aft	ofit/(loss) from Discontinued operations ter tax) (IX-X)	-	-	_	-		-	
II. Pro	fit/(loss) for the period (VIII+XI)	(10.81)	(17.19)	(11.80)	(29.03)	(23.68)	(14.79	
	ner Comprehensive Income			` ` `	(=::=/	(=0.00)	(14.7	
A. ( pro	(i) Items that will not be reclassifled to flt or loss	-	-	_			-	
be 1	ii) Income tax relating to items that will not reclassified to profit or loss	-	-	_				
B. (i	i) Items that will be reclassified to profit or	(0.19)	0.67		(1.42)	(10.18)	(0.43	
(i	ii) Income tax relating to items that will be	(0.17)	0.07	(2.30)			(****	
recl	assified to profit or loss	-	-	_			-	
(IV) XII	al Comprehensive Income for the period (+XIII)Comprising Profit (Loss) and			(14.10)	(30.45)	(33.86)	(15.21	
	er.comprehensive Income for the period )	(11.00)	(16.52)	. /	(=====)	(55.50)	(13.21	
	nority Interest	0.92	0.10	0.71	2.15	5.49	9.40	
VI. Tota	al Comprehensive Income for the period or Minority Interest (XIV-XV)	(11.93)	(16.63)	(14.81)	(32.60)	(39.35)	(24.62	
	nings per equity share (for continuing ration):						,	
(1) E	Basic	(0.14)	(0.21)	(0.15)	(0.50)			
(2) I	Diluted .	(0.14)	(0.21)	(0.15)	(0.38)	(0.36)	(0.30)	
	nings per equity share (for discontinuing ration):	(0.14)	(0.21)	(0.15)	(0.38)	(0.36)	(0.30	
	Basic	-						
- '	Diluted			-	-	-	-	
Earn	nings per equity share (for discontinuing &	-	-		-	-	•	
IX. cont	inuing operation):							
	Basic	(0.7.4)	/5					
	iluted	(0.14)	(0.21)	(0.15)	(0.38)	(0.36)	(0.30)	
		(0.14)	(0.21)	(0.15)	(0.38)	(0.36)	(0.30)	

## TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.) 4-4-231/1/2/ABC, Inderbagh, Sultanbazar, Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370



### TRIMURTHI LIMITED SCHEDULE III OF THE COMPANIES ACT 2013 PART-II

		(	QUARTER ENDE	D	NINE MONT	HS ENDED	YEAR ENDED
	Particulars	31.12.2019 (UNAUDITED)	30.09.2019 (UNAUDITED)	31.12.2018 (UNAUDITED)	31.12.2019 (UNAUDITED)	31.12.2018 (UNAUDIPED)	31.03.2018 (AUDITED)
A.	Particulars Of Share Holding						-
1.	Public Share Holding		20.00.600	29,00,600	29,00,600	29,00,600	29,00,600
	- Number of Shares	29,00,600	29,00,600		35.81%		35.81%
	- Percentage of shareholding	35.81%	35.81%	33.61 /6	33.0170		
2.	Promoters and promoter group shareholding						
	a. Pledged / encumbured				-	-	-
	- No of Equity Shares	-	-	-			
	- Percentage of Shares (of the shareholding of promoter and promoter group)	-	-	-	-	-	-
-	- Percentage of Shares (of the total share capital	-	-	-	-	•	-
	of the company) b. Non encumbured						
_		51,99,400	51,99,400	51,99,400	51,99,400	51,99,400	51,99,400
	- No of Equity Shares - Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%			100.00%	100.00%	100.00%
	- Percentage of Shares (of the total share capital of the company)	64.19%	64.19%	64.19%	64.19%	64.19%	64.19%

	Particulars	3 Months Ended ( 31/12/2019)	
B.	Investor Complaints		
_	Pending at the beginning of the quarter	-NIL-	
<u> </u>	Received during the quarter	-NIL-	
-	Disposed during the quarter	-NIL-	
-	Remaining unsolved during the quarter	-NIL-	

### **Segment Reporting**

		QUARTER ENDE	D	NINE MONT	THS ENDED	YEAR ENDED
Particulars	31.12.2019 (UNAUDITED)	30.09.2019 (UNAUDITED)	31.12.2018 (UNAUDITED)	31.12.2019 (UNAUDITED)	31.12.2018 (UNAUDITED)	31.03.2018 (AUDITED)
1. Segment Revenue				101.00	400.00	F44.64
a. Pharma Business	124.46	148.96	151.10	404.32	480.88	544.64
b. Financial Services	13.08	7.39	14.13	33.35	44.94	76.96
c. Investments	1.23	(0.07)	(0.23)	5.01	1.85	259.71
d. Foods	109.46	111.09	81.11	301.71	244.82	
e. Trading in Shares	18.41	15.08	3.56	52.62	20.83	189.63
Total	266.64	282.44	249.67	797.01	793.33	1,070.94
Less: Inter Segment Revenue	-	-	-	-	•	-
Net Sales/ Income From Operations	266.64	282.44	249.67	797.01	793.33	1,070.94
2. Segment Profits ( Before tax & Interest From	m Each Segment)					
a. Pharma Business	2.19	0.39	2.32	6.53	18.19	16.91
b. Financial Services	13.08	14.09	8.92	33.35	27.07	54.40
c. Investments	1.23	(0.07)	(0.23)	5.01	1.85	0.92
d. Foods	(13.20)	(6.12)	(28.06)	(25.43)	(82.98)	
e. Trading in Shares	(13.25	(25.97)	2.44	(45.48)	9.16	
Total	(9.95	(17.69)	(14.61)	(26.02)	(26.72)	(4.75
Less:						
i. Interest		-	-	-	-	16.01
ii. Other Un-allocable expenses net off	-	-	-	-	-	-
iii. Un-allocable Income	-	-	-	-	-	-
Total Profit Before Tax	(9.95	(17.69)	(14.61)	(26.02)	(26.72)	(20.76
3. Capital Employed						
a. Pharma Business	74.99	84.70	84.98	74.99	84.98	
b. Financial Services	369.90	449.46	450.93	369.90	450.93	521.58
c. Investments	30.19	37.14	39.39	30.19	39.39	
d. Foods	123.41	189.09	189.71	123.41	189.71	219.43
e. Trading in Shares	460.97	311.01	312.03	460.97	312.03	
Total	1,059.46	1,071.39	1,077.03	1,059.46	1,077.03	1,263.41

## TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.) 4-4-231/1/2/ABC, Inderbagh, Sultanbazar, Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370






#### Notes:

- 1 Previous period figures have been regrouped, wherever necessary, for the purpose of comparison.
- The financial results were reviewed by the Audit Committee and then approved at the meeting of the Board of Directors of the Company held on 10-02-2020
- The Consolidated Unaudited Financial Results have been prepared and subjected to Limited Review by the Statutory Auditors in accordance with Indian Accounting Standards (Ind-AS) as notified by Ministry of Corporate Affairs; Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III Division II of Companies Act, 2013. The Limited Review was carried out by Statutory Auditors for the Quarter ended 31st December 2019. The Ind AS Complaint figures for the Corresponding previous Quarter ended 30th September 2019 have not been subject to review or audit, however the Company's management has exercised necessary due deligence to ensure that such financial results provide a true and fair view of its affairs.
- 4 The results are also available on the webiste of the Company

Place: Hyderabad Date: 10-02-2020



(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.) 4-4-231/1/2/ABC, Inderbagh, Sultanbazar, Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370



Tel.

: (91-40) 2332 6666, 2331 2554

2339 3967, 2332 1470

Fax

: (91-40) 2339 2474 : pmurali.co@gmail.com E-mail

info@pmurali.com

Website: www.pmurali.com


# Limited Review Report - Consolidated Financial Results

To The Board of Directors, Trimurthi Limited, Hyderabad.

Limited Review Report on unaudited consolidated financial results for the Quarter and Nine month ended 31th December 2019

- We have reviewed the accompanying statement of unaudited consolidated 1. financial results ("the statement") of Trimurthi Limited Group comprising Trimurthi Limited ("the Parent") and its subsidiaries (together referred to as 'the Group'), for the quarter ended 31th December 2019 and year to date results for the period 1stApril 2019 to 31th December 2019 ("the Statement")attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including relevant circulars issued by SEBI from time to time.
- The preparation of "the Statement" in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company in their meeting held on 10th February 2020. Our responsibility is to express a conclusion on "the Statement" based on our review.
- We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular issued by the Securities and Exchange board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015as amended, to the extent applicable



: (91-40) 2332 6666, 2331 2554 Tel.

2339 3967, 2332 1470

: (91-40) 2339 2474 Fax E-mail: pmurali.co@gmail.com

info@pmurali.com Website: www.pmurali.com

The consolidated unaudited results include the results of the following entities: 4.

- (a) Trimurthi Foods Limited (wholly owned subsidiary )
- (b) Trimurthi Pharmaceuticals India Private Limited (subsidiary )
- Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation, read with Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali& Co. Chartered Accountants

FRN: 007257S

VHOSHI

Partner M.No. 024784

UDIN: 20024784AAAABY6448

Place: Hyderabad Date: 10-02-2020